United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$331.04 USD
+8.81 (2.73%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $330.84 -0.20 (-0.06%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
Brokerage Reports
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 421 - 440 ( 601 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 27th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q1:15 Preview: We Believe Consensus Revenues Are Achievable; Reiterate OUTPERFORM and $198 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Legal Perspective on Remodulin?s IP Litigation (Part I)
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Our Thoughts on Yesterday?s Selexipag/GRIPHON Data from ACC
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of March 16th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Unituxin Approval by the FDA Comes with Highly Valued Pediatric Priority Review Voucher; Reiterate OUTPERFORM and Raising PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
March and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
March and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
We Reiterate our Buy Rating and Raise PT to $175
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q4:14 Preview: We Believe Consensus is Achievable and Look for Pipeline Update; Reiterate OUTPERFORM and $171 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb 9
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
January and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec 29
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
United Therapeutics Plans to Submit sNDA for Remodulin in January 2015; Reiterate OUTPERFORM and $171 PT.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
LIFE SCIENCES AND HEALTH CARE - The Week Ahead in Life Sciences- Upcoming Events for the Week of Dec 22
Provider: WEDBUSH SECURITIES INC.